September 30, 2026. Educational public-health analysis, not personal medical advice or a verdict on an unnamed hospital's policy.
Read the edges as current vaccine strategies. Smallpox is the historical reference; groups are a synthesis, not an official classification. Product-specific benefits and caveats remain in the underlying dataset.
Editorial groups, not a mandate score. Smallpox is historical.
| Disease | Current strategy / status | Mechanism |
|---|---|---|
| Measles | Elimination goal, not globally eradicated | Community-wide vaccination limits spread; high equitable two-dose coverage needed. |
| Polio | Global eradication target; not complete | IPV prevents paralytic disease; OPV intestinal immunity helps interrupt transmission, with different live-virus risks. |
| Smallpox | Historically eradicated in 1980 | Historical vaccination and surveillance success; current routine general-public vaccination not recommended. |
| Seasonal influenza | Recurring burden reduction | Seasonal effectiveness and viral changes; severe outcomes prevented without an eradication program. |
| Pertussis | Recurring disease with waning immunity | Protection wanes; maternal vaccination serves infant protection; no eradication inference. |
| Tuberculosis | Not eradicable through current BCG strategy | Partial severe-childhood protection; poor adult/adolescent protection where most transmission occurs. |
| Tetanus | Environmental exposure remains | No person-to-person transmission; direct protection is not herd immunity. |
| HPV | Pre-exposure infection prevention | Prevents new infections, not treatment; long-term cancer prevention strategy. |
United States, 2024-25 season. CDC March 12, 2026 report snapshot. Modeled, preliminary estimates. Each panel has a separate scale. These are not per-person risks, a clinical-trial comparison, or a live dashboard.
Source CDC 2024-25 season summary. Prevented outcomes are estimated separately from outcomes that occurred.
Six selected jurisdictions, checked September 30, 2026. Sort by childhood list breadth, not policy quality or severity. Instruments, exemptions and pending rules remain visible.
| Jurisdiction | Child policy scope | Instrument | Exemptions / alternatives | Worker policy | Evidence |
|---|---|---|---|---|---|
| Francecountry | Broad, birth-cohort-specific list | Admission requirement | Medical; provisional admission | Flu obligation pending implementation, not yet fully enforceablePending regulatory framework | P1, P10, P11 |
| Germanycountry | Measles-specific protection proof | Proof, fines, specified restrictions | Immunity or medical contraindication | Measles protection in covered facilities, birth-after-1970 scopeEffective requirement | P2 |
| Finlandcountry | General participation voluntary | Voluntary general vaccination | Worker exceptions case-specific | Vulnerable-patient roles: measles/varicella, flu; pertussis for infant careTargeted requirement, exceptions | P3, P4 |
| EnglandUK nation | Consent-based school program | Offer and consent | Not applicable to cited offer | Frontline flu offer and encouragement in national letterProgram guidance; no blanket mandate in letter | P5, P6, P14 |
| Australiacountry with state variation | Broad childhood schedule for benefits | Financial eligibility; state-varying childcare access | Approved exemptions / catch-up; objection not valid for federal condition | National recommendations; state rules may go furtherRecommendation at national guidance layer | P7, P8, P12 |
| Idaho (US)US state | Multiple school/daycare immunisations | Records or exemption | Medical, religious, other reasons | Not researched at employer levelUnknown for unnamed hospital | P9 |
September notice expects enforceable framework after regulatory work by end-Q1 2027. Do not code HAS recommendation as enacted law.
Compulsory-school children are not excluded like daycare entrants; forced vaccination excluded.
Current THL guidance corroborates older Act translation; Finnish/Swedish text is legally binding.
Not a claim about every employer condition. Older parliamentary overview only historical context.
Queensland childcare services can choose restrictions; this is not a uniform national school-admission law.
State is not a US-wide country score; broad exemptions change force of requirement.
Broad lists: France, Australia benefits, Idaho. Targeted measles proof: Germany. Voluntary/consent programs: Finland, England. The same order does not rank enforcement: Idaho allows broad exemptions; Australia has financial and subnational instruments. France's worker flu obligation is not yet fully enforceable in the September notice.
The eradication-versus-management distinction is real. It describes one part of vaccination's public benefit, not a complete ranking of vaccines or a rule for mandates. A better comparison separates the disease, the vaccine product, the population, the outcome and the setting. Measles vaccination can interrupt transmission; polio is a global eradication target; current tuberculosis vaccination is not in the same category. Flu vaccination manages recurring risk, but its benefit can still be large. Tetanus is the counterexample that breaks the binary: vaccination protects people against a dangerous disease that does not spread from person to person.
The useful question is not "Which vaccine is most important?" It is "Which harm does this product prevent, for whom, for how long, and with what evidence?"
These are editorial groups built from the evidence, not an official WHO classification. A disease can belong to several groups. They describe mechanisms and goals, not moral worth or mandate strength.
| Job | Examples | Public benefit | What it does not establish |
|---|---|---|---|
| Stop transmission toward elimination or eradication | Measles, polio; smallpox as the historical success | Fewer infections now and potential protection for future generations | That a pathogen is already gone, or that vaccination alone is enough |
| Reduce a recurring disease burden | Seasonal influenza; pertussis as a waning-protection example | Fewer illnesses and severe outcomes even when circulation continues | That transmission is completely prevented, or that benefit is small |
| Protect against severe disease where infection control remains difficult | Current BCG against TB | Protection against serious childhood TB | That current BCG can stop adult pulmonary transmission and eradicate TB |
| Protect directly from an environmental hazard | Tetanus | Strong individual protection; newborn/maternal protection also matters | A person-to-person herd-immunity argument |
| Prevent infection that can lead to cancer later | HPV | Prevention of new HPV infections and future disease | Treatment of existing infection, or elimination of every HPV type |
Smallpox is a historical reference, not a routine vaccine recommendation for today's general public. WHO records eradication in 1980; CDC does not recommend routine smallpox vaccination for the general public. [S24, S25]
WHO calls measles highly contagious and identifies community-wide vaccination as the most effective prevention. CDC reports two MMR doses are 97% effective against measles. WHO's position paper recommends at least 95% coverage with both doses in every district for countries aiming at elimination. These numbers are different: 97% is vaccine effectiveness; 95% is a program coverage target. Neither is a guarantee for every person or community.
Elimination is not worldwide eradication. Imported cases and pockets of susceptibility can produce outbreaks. Sustained vaccination, surveillance and outbreak response remain necessary. The payoff includes avoiding pneumonia, encephalitis, blindness and death, with severe complications concentrated in young children and some other vulnerable groups. [S1, S2, S3]
WHO identifies global eradication as the goal. Its April 2025 fact sheet reports wild-poliovirus cases down more than 99% from 1988, but continuing endemic transmission in Afghanistan and Pakistan. This is a dated status observation, not a live September 2026 case count. One in 200 infections can lead to irreversible paralysis; among those paralysed, 5-10% die when breathing muscles become immobilized.
Inactivated polio vaccine (IPV) and oral polio vaccine (OPV) cannot be collapsed into one node. CDC describes IPV as highly effective against paralytic disease but less effective than OPV at inducing intestinal immunity. OPV's intestinal protection helps reduce shedding and transmission. Its live vaccine virus creates different rare risks, including vaccine-associated paralytic polio and vaccine-derived outbreaks in underimmunized populations. IPV does not cause vaccine-associated paralytic polio. A graph must attach benefits and risks to the product, not simply to "polio vaccine." [S4, S5]
TB is not a good example of a disease that present vaccination can practically wipe out. WHO's current research page says neonatal BCG gives partial protection against severe TB in infants and young children, but does not protect the adolescents and adults responsible for most transmission. CDC notes variable effectiveness against adult pulmonary TB and explains why BCG is not generally used in the US. Detection, treatment, prevention of progression and better vaccines remain part of the problem.
WHO's March 2026 fact sheet estimates 10.7 million people developed TB and 1.23 million died globally in 2024. These are global burden estimates, not comparable to a US seasonal flu death count. The lesson is that a large burden does not imply a vaccine has the transmission effect needed for eradication. [S6, S7, S8]
Flu viruses change; influenza A also circulates in animals. With present seasonal vaccines and current ecology, influenza vaccination is a burden-reduction strategy, not an eradication program. "Never" would be an unnecessary claim about all future technology.
CDC's March 12, 2026 report estimates the US 2024-25 season caused 51 million illnesses, 710,000 hospitalizations and 45,000 deaths. Vaccination is estimated to have prevented another 10 million illnesses, 180,000 hospitalizations and 12,000 deaths. These are modeled estimates; the report says the season's burden estimates remain preliminary. They do not directly measure the risk for a healthy doctor or predict next season. CDC attributes 71% of estimated deaths to adults 65 and older, and estimates 790 pediatric deaths. "It doesn't kill many people" is not an accurate summary of that season. [S9, S10]
Effectiveness depends on season, age, vaccine and outcome. Preventing an outpatient visit, infection, hospitalization and death are distinct endpoints. Do not put one flu effectiveness number beside measles effectiveness without specifying all of those dimensions.
CDC states that tetanus spores occur in the environment and enter through wounds. It does not spread from person to person. Protection against tetanus therefore cannot rely on vaccinated neighbors interrupting a chain of person-to-person transmission. This distinguishes the argument for individual vaccination from a harm-to-others rationale for requiring it. It does not make the disease harmless or vaccination unimportant. [S11]
CDC states HPV vaccination prevents new infections and does not treat existing infections or disease; it works best before exposure. This is a different timing problem from a seasonal respiratory vaccine. Infection prevention and later cancer prevention belong on different outcome nodes, with a long delay between them. [S12, S26]
CDC reports protection following Tdap wanes after a few years and recommends Tdap during every pregnancy. This illustrates why "childhood disease" and "eradicable with current vaccination" are not interchangeable categories. The same combination vaccine can also serve a different purpose: adult Td/Tdap boosters maintain tetanus and diphtheria protection. [S13]
Use the same population, time horizon, outcome definition and denominator on both sides. A disease complication rate among infected people is not a risk per unvaccinated person. A vaccine adverse-event rate per dose is not a lifetime risk. Observational reports after vaccination do not by themselves prove vaccination caused the event.
| Product | Documented vaccine-side concern | Important qualification |
|---|---|---|
| MMR | Common transient symptoms; small increased febrile-seizure risk, about 1 in 3,000-4,000 vaccinated children; rare serious allergic reactions | CDC says these febrile seizures are not associated with long-term effects. Live-vaccine contraindications matter. |
| Seasonal flu | Common mild reactions; possible small GBS increase in some seasons, on the order of 1-2 additional cases per million doses | CDC describes the association as varied and inconsistent. Infections can also precede GBS. Product and prior medical history matter. |
| Polio IPV versus OPV | OPV-specific rare paralysis and vaccine-derived-virus risks; IPV has a different safety profile | Do not imply US IPV creates OPV's live-virus risk. |
| BCG | Live-vaccine contraindications, including immunosuppression; can complicate interpretation of TB skin tests | A false-positive skin test is not the same outcome as vaccine injury; use TB blood testing guidance. |
| Td/Tdap/DTaP | Usually mild effects; rare serious allergic reactions | Product, age and contraindications need to remain explicit. |
| HPV | Injection-site reactions and fainting around vaccination | CDC recommends observation to avoid injuries from fainting. |
| Smallpox vaccines | Product-specific risks; replicating vaccinia vaccine can have serious complications | Routine smallpox vaccination is not recommended for the general public now. Eradication changes today's benefit-risk balance. |
This table is not a complete clinical safety guide. It samples distinctions that a one-score comparison would erase. [S5, S7, S12, S14, S15, S16, S17]
The non-vaccination side includes the person's own disease risk, risk to others where transmission matters, long-term disability, outbreaks, healthcare demand and lost work. The vaccination side includes benefits, adverse effects, administration burden, contraindications and access costs. A decision about a mandate adds further risks: exclusion from work or school, unequal access, loss of trust and effects on staffing. Those policy effects require their own evidence.
For a credible quantitative comparison across vaccines, choose a place, age/risk cohort, vaccination product/schedule, endpoint and horizon first. Without those, show a mechanism matrix, not a made-up league table. [S18, S19]
Eradication is an extra public-good benefit, not a necessary condition for justified requirements. Conversely, a vaccine's strong personal benefit does not automatically establish that forcing it is justified.
Use a separate decision lens: 1. Name the objective: protect vulnerable patients, reduce infections, preserve hospital capacity, prevent school outbreaks, or protect the recipient. 2. Require evidence for that objective in the affected population. Evidence against hospitalization is not automatically evidence of transmission prevention. 3. Compare the proposed requirement with alternatives that can achieve the objective, including access improvements and infection-control measures. 4. Examine safety, contraindications, free and practical access, and fair treatment of people with medical exemptions. 5. Account for staffing, equity, trust, enforcement consequences and a review or end condition.
WHO's 2022 mandatory-vaccination brief supplies this ethical structure, but is explicitly about COVID-19. Applying its structure here is our synthesis, not a WHO endorsement of any particular flu policy. [S20]
CDC calls annual vaccination an important step in preventing healthcare influenza transmission and recommends a layered program including vaccination, symptom policies, respiratory hygiene, precautions and other infection-control practices. Its guidance describes mandates among several strategies that increase coverage. That is not proof that every mandate produces a particular patient-mortality reduction.
Evidence on vaccinating healthcare workers must also be read by setting and endpoint. A Cochrane review focused on older residents in long-term care is not automatically a trial of this doctor's hospital, its policy or its deadline. Keep the strength of evidence visible, not just the institutional recommendation. [S21, S22]
The hospital and deadline have not been identified, so there is no local-policy verdict. The fetched CDC guidance, still labeled 2025-26, favors September or October for most groups and warns against unnecessarily early vaccination for many adults because protection can wane. England's current 2026-27 guidance independently starts frontline staff offers from October 1. A later deadline might have a sensible timing rationale; it must be checked against the actual policy rather than guessed. [S23]
A bipartite graph links eight disease nodes to five job nodes. A second layer links disease to vaccine product, product to supported outcome and to safety caveat, and every factual edge to its source. Labels say "current vaccine strategy," "historical eradication," or "editorial grouping" so readers cannot mistake grouping for proof.
The quantitative companion uses three separate paired bars for the US 2024-25 flu season: illnesses, hospitalizations and deaths. Each panel shows occurred and estimated prevented, with its own units and source date. It does not compare unlike diseases or equate a vaccine harm rate with an annual disease count. An accessible table exposes the underlying numbers.
The Instinct-only version will remain distinct and frozen for comparison. The unified page should link to both independent versions and explain which findings changed after review. Public publication and the actual OnlyData implementation are still pending. This independent version is frozen before comparison; the next version will record any factual corrections separately.
A local doctor friend's challenge was that disease impact, rather than unproven categories, should drive decisions. That is a good warning against intuitive buckets masquerading as evidence. If "impact" includes baseline risk, severity, vaccine effectiveness, transmission, future disability, delivery cost and policy consequences, then the two views largely converge: those dimensions are what the proposed groups summarize. If impact means only today's death count, it misses durability, disability and external effects.
The groups add value only if they help predict a relevant outcome or explain a tradeoff. They should not override the underlying data. The finding is not that childhood vaccines deserve one uniform rule and flu deserves another. It is that disease-product-setting combinations produce different reasons for vaccination and different reasons for a requirement.
This is a purposive comparison of six jurisdictions, not a representative country survey. Idaho is a state, England is one UK nation, and Australia's childcare rules vary by state and territory. Policies below were checked September 30, 2026. Sources differ in date; the policy page should carry those dates and a recheck flag. A recommendation, a legal requirement and an employer's condition must remain distinct.
| Jurisdiction | Child / school approach | Adult / worker approach in the sources | What this tests |
|---|---|---|---|
| France | Birth-cohort-specific mandatory childhood vaccines for admission to school/childcare, medical exceptions and provisional admission | Flu is recommended. HAS recommended a healthcare-worker obligation in July 2026; a September ministry notice says the fully enforceable framework awaits regulations expected by end-Q1 2027 | Current-policy change can be evidence-informed; a recommendation is not yet an enforceable mandate |
| Germany | Measles-protection proof in covered child settings; immunity/medical contraindication can satisfy the rule; compulsory-school pupils are not simply excluded like daycare entrants | Measles proof also covers relevant workers born after 1970, including healthcare settings; fines and specified work restrictions, not forced injection | Disease-specific externality and setting drive scope, not a uniform all-vaccine requirement |
| Finland | General vaccination participation is voluntary under the translated Act | Section 48 protects vulnerable patients: measles/varicella protection, influenza vaccination, and pertussis vaccination for infant care; inadequately protected workers only in exceptional circumstances | A non-eradicable disease can justify a narrowly targeted patient-protection requirement |
| England | Consent-based school immunisation programs in current guidance | 2026-27 national flu letter says offer and encourage vaccination for frontline healthcare staff, with an employer duty to make it accessible; not a blanket flu requirement in that letter | Public benefit can be pursued through an organized offer rather than enforcement |
| Australia | National family-assistance benefits depend on childhood immunisation/catch-up/approved exemptions. Childcare entry rules differ by state | National healthcare-worker guidance recommends vaccines and employer encouragement; state rules may go further | Financial conditions, admission restrictions and recommendations are different policy instruments |
| Idaho, US | School/daycare records or exemptions; medical, religious and other exemptions recognized | No unnamed hospital policy is inferred from school law; employer requirements require separate checking | A broad vaccine list can coexist with broad exemptions, making a simple "mandatory yes/no" misleading |
For England, the 2022 parliamentary briefing describing vaccines as non-mandatory is historical context, not the sole proof of current law. The current school guidance and 2026-27 flu program establish the described offer/consent approach; they do not prove the absence of every possible employer condition. Finland's translated Act is not legally authoritative over Finnish/Swedish text; current THL guidance corroborates the section-48 approach. France's 2026 update is particularly important: the May public-service page was superseded in context by a July recommendation and September implementation notice. [P1, P2, P3, P4, P5, P6, P7, P8, P9, P10, P11, P12, P13, P14]
A visual can sort policies by an explicitly defined feature, without declaring a country "best": - Childhood vaccine-list breadth: targeted disease versus multiple childhood diseases versus consent-based offer. - Consequence: recommendation/offer, documentation, financial eligibility, restricted access/work, fines. These are categorical instruments, not an ethically ordered numeric scale. - Non-medical exemption availability: yes, no, mixed, not verified. - Worker scope: none demonstrated by the cited program, particular vulnerable-patient roles, broad covered facilities, pending regulation. - Legal status: effective law, program guidance, authority recommendation, or pending implementation.
For each sort, unknowns remain unknown. There is no defensible single international enforcement score without arbitrary weights. The proposed visual is a sortable policy matrix with a companion targeted-versus-broad ordering for childhood requirements. It satisfies the ranking question while exposing what the ranking means. It is not a ranking of vaccine uptake, health outcomes, liberty, or policy quality.
The cross-country differences are inconsistent with biology alone determining every rule. They support the need to consider institutions, legal traditions, trust, past programs and practical implementation. They do not, by themselves, prove which of those factors caused each difference or that any policy is irrational.
Germany's targeted measles rule, Finland's vulnerable-patient flu rule, and France's broad child requirements show why a single eradicable/non-eradicable split cannot explain policy. France also includes tetanus, which lacks person-to-person spread. Existing combination vaccines and established schedules may make policy bundles convenient, but convenience is not evidence that every component has the same externality.
A clean test of the status-quo hypothesis is counterfactual: starting without any historical mandates, name the public objective for each setting, estimate the incremental benefit of this particular requirement over realistic alternatives, and apply the same safety, access, proportionality and review criteria. Then compare that result with current rules. Our descriptive international sample cannot estimate that counterfactual causal effect. It can show where the arguments and policy choices diverge.
The February 2025 Cochrane review of four long-term-care trials, 8,468 residents, reports uncertainty in influenza-specific resident outcomes. It observes a lower all-cause mortality rate but could not explain it through the influenza-specific outcomes. In July 2026, France's HAS nevertheless recommended a phased worker flu obligation using a broader evidence and ethical assessment, low staff uptake and high resident vulnerability. That is an evidence-to-policy judgment under uncertainty, not something to erase by selecting only one source. Neither proves the exact effect of this doctor's hospital policy. [S22, P10]
P14: UK vaccine consent guidance. Source date: 2025-11-04; retrieved September 30, 2026.
S26: CDC HPV clinical overview. Source date July 9, 2024; retrieved September 30, 2026.